Bloomberg reported on August 29 that hair-loss drug stocks are surging as Wall Street bets on a new pharmaceutical goldmine following the GLP-1 weight-loss boom.
Shares of Veradermics, Incorporated (NYSE:MANE) have climbed nearly 500% since its February 2026 initial public offering, while Absci Corporation (NASDAQ:ABSI)’s stock has more than doubled so far in 2026.
Switzerland’s Cosmo NV also posted positive trial results for an experimental male hair-loss treatment, though its shares have lagged the U.S. competitors. Pattern hair loss affects an estimated 50 million men and 30 million women in the U.S., and no new hair-loss drug has won FDA approval since the late 1990s. It leaves patients with only older options like topical minoxidil and prescription finasteride, both of which carry side effects including heart palpitations and lowered sex drive.
Veradermics reported positive results in April for an oral minoxidil tablet in men and followed with promising mid-stage data for women with thinning hair in July, potentially positioning it as the first approved pill for female-pattern hair loss. Jefferies analyst Roger Song holds the Street’s highest price target on the stock.
Copyright: wasansos1 / 123RF Stock Photo
Bull Case
The addressable market is large and genuinely underserved. Roughly 80 million Americans experience pattern hair loss, yet no new drug has reached the market in nearly three decades. That gap leaves substantial unmet demand in a category that Wall Street has largely ignored.
Veradermics, Incorporated (NYSE:MANE) has cleared two important clinical hurdles this year. Positive results in men in April followed promising mid-stage data in women in July, reducing some of the clinical risk that typically accompanies an early-stage biotech. The results could also position Veradermics to become the first company to win approval for an oral treatment for female-pattern hair loss, since no approved pills currently target that condition.
Analysts see room for multiple winners in the hair-loss market. Jefferies argues that patients often combine treatments, which could allow several approved drugs to generate meaningful sales. That dynamic could create a large market for multiple companies rather than forcing investors to identify a single winner.
Existing treatments also leave room for improvement. Minoxidil and finasteride have struggled with tolerability and limited adoption, giving a more effective and better-tolerated oral treatment an opportunity to take share from established options rather than compete as another me-too product.
Absci Corporation (NASDAQ:ABSI) gives investors another potential way to benefit from the growing hair-loss drug market. The firm is developing an AI-designed injectable treatment. It gives it a differentiated approach as drugmakers pursue alternatives to traditional hair-loss therapies. A large commercial opportunity in the category, which could give Absci significant upside if its treatment gains traction and competes effectively.
Bear Case
Veradermics, Incorporated (NYSE:MANE)’s stock rally has outpaced its clinical evidence. The company remains in early- and mid-stage development without FDA approval, while its shares have gained nearly 500% since its February IPO. That valuation already reflects substantial expectations for success, leaving the stock vulnerable to disappointment if pivotal trials produce weaker results.
The commercial model lacks the safety net that GLP-1 drugs received from established medical demand. Hair loss does not qualify as a medical necessity, so patients would likely pay out of pocket for an approved treatment. That structure could limit adoption and make consumers more sensitive to price than patients who receive insurance coverage for medically necessary treatments.
Veradermics also faces competition from other drug developers. Absci Corporation (NASDAQ:ABSI) is developing an AI-designed injectable treatment, while Cosmo NV plans to seek regulatory approval for its topical treatment in early 2027. Jefferies estimates a $3 billion sales opportunity for Cosmo’s drug alone, giving Veradermics another competitor as it tries to establish its position.
The comparison with GLP-1 drugs sets an exceptionally high bar. Calling hair loss “the next Ozempic” and comparing the opportunity with the trillion-dollar valuations of Eli Lilly and Novo Nordisk could create unrealistic expectations. Hair loss represents a more price-sensitive market than obesity treatment because patients generally pay out of pocket, which could limit the category’s ability to replicate the scale of the GLP-1 boom.
Absci Corporation (NASDAQ:ABSI) faces competition as it tries to establish its position in the hair-loss market. Veradermics has already produced positive clinical data, while Cosmo NV plans to seek regulatory approval for its topical treatment in early 2027. Absci needs its AI-designed injectable to demonstrate clear advantages in effectiveness and tolerability to win patients as competitors enter the market.
Hedge Fund Data
Insider Monkey’s database shows Veradermics, Incorporated (NYSE:MANE) was held by 37 hedge funds in the second quarter of 2026, up from 30 in the first quarter. Absci Corporation (NASDAQ:ABSI)’s fund count rose to 39 from 23. Both stocks are drawing rapidly increasing hedge fund attention.
Conclusion
The growing hair-loss market gives Veradermics and Absci a significant opportunity to develop new treatments for a large underserved patient base. However, clinical uncertainty, out-of-pocket costs, and high competition could keep the market from matching the scale of the GLP-1 boom. Investors should watch whether these companies can turn promising treatments into commercially successful products.
READ NEXT: Meta’s $18 Billion Teen Safety Deal Puts the Pressure on TikTok and YouTube Next and Tesla (TSLA) Rolls Out its Safety Numbers ahead of a Make-or-Break EU Vote.
Hedge Fund Resource Center